Levo Product Joins List Of Prader-Willi Syndrome Trial Failures
But Company Confident About Lower Dose Of Intranasal Carbetocin
Executive Summary
Attempts at developing an effective therapy for PWS, and the abnormal desire for food associated with the rare disorder, have been fruitless but Levo Therapeutics' enthusiasm for LV-101 remains high, despite a Phase III setback.
You may also be interested in...
Tech Transfer Roundup: MD Anderson Working To Unlock Promise Of Tumor-Infiltrating Lymphocytes
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
Soleno Shaken By FDA Demand For Second DCCR Phase III Trial In PWS
The US FDA has asked Soleno to conduct another Phase III Study evaluating its chief asset in Prader-Willi syndrome patients prior to any NDA submission, rattling investors and clouding the company’s prospects.
Bayer Bigs Up Vitrakvi In Comparison With Roche's Rozlytrek
In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.